UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $7.35 Million Holdings in Dianthus Therapeutics, Inc. $DNTH

Key Points

• UBS Asset Management increased its Dianthus Therapeutics stake by 24.8% in the second quarter, holding 75,396 shares valued at approximately $7.35 million. Institutional investors collectively own 47.53% of the company.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $126.92; target prices include $131 from Raymond James and $158 from HC Wainwright.
• Dianthus reported a quarterly loss of $0.90 per share, missing estimates of $0.85, although revenue of $0.76 million exceeded expectations. Meanwhile, insiders sold roughly $29.7 million worth of shares during the last quarter.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 24.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,396 shares of the company's stock after purchasing an additional 14,961 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.14% of Dianthus Therapeutics worth $7,350,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at $27,000. First Horizon Corp bought a new stake in Dianthus Therapeutics during the 1st quarter worth about $32,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Dianthus Therapeutics during the 4th quarter worth about $40,000. EFG International AG bought a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $49,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at about $64,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Insiders Place Their Bets

In other Dianthus Therapeutics news, Director Anne McGeorge sold 7,750 shares of the company's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the transaction, the director directly owned 1,250 shares in the company, valued at $136,262.50. The trade was a 86.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Simrat Randhawa sold 23,124 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the completion of the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $425,640. The trade was a 85.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 283,678 shares of company stock worth $29,672,400 in the last quarter. Company insiders own 3.02% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on DNTH. Raymond James Financial reiterated a "strong-buy" rating and set a $131.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. Guggenheim reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Wolfe Research reissued an "outperform" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, HC Wainwright raised their target price on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Dianthus Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $126.92.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH opened at $108.10 on Tuesday. The business's 50 day moving average price is $105.48 and its two-hundred day moving average price is $89.79. The company has a market cap of $5.91 billion, a PE ratio of -26.05 and a beta of 1.24. Dianthus Therapeutics, Inc. has a twelve month low of $24.49 and a twelve month high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The business had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. As a group, research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.